sotrovimab
Selected indexed studies
- Sotrovimab. (, 2006) [PMID:34165945]
- Sotrovimab: First Approval. (Drugs, 2022) [PMID:35286623]
- Sotrovimab for COVID-19. (Aust Prescr, 2021) [PMID:34728886]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sotrovimab. (2006) pubmed
- Sotrovimab: First Approval. (2022) pubmed
- Sotrovimab for COVID-19. (2021) pubmed
- Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants. (2024) pubmed
- [Sotrovimab in controlling SARS-CoV-2 infection]. (2022) pubmed
- Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events. (2022) pubmed
- PMID:38502756 (2023) pubmed
- Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials. (2024) pubmed
- Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis. (2023) pubmed
- PMID:40112123 (2024) pubmed